PAR

6.98%

20.0¢ paradigm biopharmaceuticals limited..

Ann: Paradigm delivers IND to US FDA for Pivotal OA Program, page-43

First 43 Last

Share
Profile

Follow
Darksky

142 Posts.

33

27/03/21

17:26

Post #: 52086364
Share

Originally posted by Darksky: ↑

You never go broke taking a profit, I can't remember who gave me that advice but it's good,

But back to the prospect of having a substantial short position in a stock with tremendous potential IMHO.

What kind of a gap up in price might we expect if the IND for Zilusol is approved?!
I have absolutely no idea. But we are talking about a drug that has been test successfully (on evidence provided here) with over 600 SAS patients, has a long safety record in use with animals, has already caught the attention of pharmaceutical companies (again evidence here) and has a very significant market for it's use.

So, say I was running a managed fund I was short 10 million shares and had the financial capacity to run the price up and down and shake the odd loose holder out from time to time to help cover some of my position and make and book profits month by month along the way and meet my trading profit targets for managerment. What would happen if PAR receives early approval for the IND? would the share price gap up at open (remembering the FDA is in America and their announcement may occur in US time) by $2.50 to $3.00, I really don't know, but if you're short 10 million shares that's a $25 to $30 million loss. And then, what if that announcement was quickly followed by a significant deal with big pharma? Again I have absolutely no idea what that would do to the price. But what if it was an additional $5 gap up that's a potential combined loss of $75 to $80 million. Ouch!!!, and if it's an additional $10 gap up that's potentially a total loss of $125 to $130 million on the one position. Now if I was an agressive fund manager without a position in PAR and I could see the large short position and understood all the evidence about the drug, would I/they see that as an apportunity to put a short squeeze into play. I really don't know, I'm not a fund manager.But If that did occur (depending on the size of the fund) that loss could put their fund into the bottom quartile relative to their peers for quite a while. IMHO DYOR. Anyway, lets just say that a squeeze might just put a STOP to their GAME.
imho dyor

Expand

The perfect storm approaches...

a drug that has been test successfully (based on evidence provided here) with over 600 SAS patients, has a long safety record in use with animals, has already caught the attention of pharmaceutical companies (again evidence here) and has a very significant market for it's use...

AND COMPETITION HAS JUST BEEN ELIMINATED!!!

PAR Price at posting: $2.65 Sentiment: Buy Disclosure: Held
19 Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 9 more messages in this thread...

First 43 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.015(6.98%)		Mkt cap ! $70.04M

Open	High	Low	Value	Volume
21.0¢	21.0¢	20.0¢	$201.6K	994.6K

Buyers (Bids)

No.	Vol.	Price($)
15	429247	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	13806	2

View Market Depth

No.	Vol.	Price($)
12	389247	0.200
8	133607	0.195
17	238789	0.190
4	92160	0.185
8	122773	0.180

Price($)	Vol.	No.
0.210	13806	2
0.215	28509	1
0.220	59615	6
0.225	28604	2
0.230	16334	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PAR (ASX) Chart

Ann: Paradigm delivers IND to US FDA for Pivotal OA Program, page-43

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Paradigm delivers IND to US FDA for Pivotal OA Program, page-43

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News